TCTR20171128005CompletedNot Applicable
PREVALENCE SURVEY OF PLASMODIUM FALCIPARUM ANTIMALARIAL DRUG RESISTANCE MARKERS AT SITES IN INDIA
Conditions
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- St. John Research Institute
- Enrollment
- 400
Study Overview
Brief Summary
The results indicate that artesunate + sulphadoxine-pyrimethamine, the artemisinin-based combination therapy (ACT) used as the first-line antimalarial treatment, is likely to be efficacious. However, there appears to be a high prevalence of the molecular markers seen in recrudescent parasites following treatment with lumefantrine. These results will be completed with testing for additional mutations in pfmdr1 and pfcrt genes known to be associated with such recrudescence.
Study Design
- Study Type
- Observational
Eligibility Criteria
- Ages
- 6 Months to 75 Years (—)
- Sex
- All
Inclusion Criteria
- •Participants must meet all of the inclusion criteria to participate in the study.
- •-Patients (6 months - 75 years) with confirmed uncomplicated P. falciparum infection
- •-Written informed consent obtained
- •All participants meeting inclusion criteria will have their dried blood spots retained for parasite molecular analyses.
Exclusion Criteria
- •Patients presenting signs of severe malaria will be excluded from the survey to prevent any delay in the management of the patient.
Investigators
Similar Trials
Completed
Not Applicable
A Randomised Efficacy Study of Combination Antimalarials to Treat Uncomplicated MalariaMalariaNCT00203814University of Cape Town280
Completed
Not Applicable
Artemisinin-resistant Malaria in CambodiaPlasmodium Falciparum MalariaNCT01736319National Institute of Allergy and Infectious Diseases (NIAID)561
Completed
Phase 3
Artesunate-pyronaridine and artemisinin-naphthoquine combination therapies for Papua New Guinean children with uncomplicated malaria infectionsInfection - Other infectious diseasesMalariaACTRN12610000913077niversity of Western Australia637
Withdrawn
Phase 4
Efficacy and safety of artemisinin-based combinations: artesunate+amodiaquine and artemether+lumefantrine for the treatment of uncomplicated Plasmodium falciparum in the sites of BUHIGA, KAZIRABAGENI and KIGOBE MUTOYI in KARUZI , MAKAMBA, BUJUMBURA MAIRIE et GITEGA provinces, respectively, BURUNDIMalariaACTRN12616001006437Ministry of Health of Burundi528
Completed
Phase 4
Efficacy and safety of artesunate+sulfadoxine/pyrimethamine and artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in At Tur Bani Qa'is, Harad, Almusaymir, Jabal Ash Sharq, Al Udayn and Bajil districts in YememalariaInfection - Studies of infection and infectious agentsPublic Health - EpidemiologyACTRN12610000696099Ministry of Public Health and Population522